Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Cellular Biomedicine Group, Inc. | cbmg_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): May 1, 2017
(April 28, 2017)
CELLULAR BIOMEDICINE GROUP, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-36498
|
|
86-1032927
|
|
(State
or other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
19925 Stevens Creek Blvd., Suite 100
Cupertino, California
|
|
95014
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (408)
973-7884
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 5.07 Submission of Matters to a Vote of
Security Holders.
On
April 28, 2017, Cellular Biomedicine Group, Inc. (the
“Company”) completed its 2017 annual meeting of
stockholders (the "Annual Meeting"). The number of shares of common
stock entitled to vote at the Annual Meeting was 14,281,350 shares.
The number of shares of common stock present or represented by
valid proxy at the Annual Meeting was 9,384,155 shares. All matters
submitted to a vote of the Company's stockholders at the Annual
Meeting were approved, and Chun Kwok Alan Au, Gang Ji and Bizuo
(Tony) Liu were elected “Class II”
directors.
The
following is a tabulation of the voting on the proposals presented
at the Annual Meeting:
(i) To
elect three (3) “Class II” directors, each of whom will
be elected for a term of three years, or until the election and
qualification of their successors.
|
Nominee
|
|
Shares Voted For
|
|
Shares Withheld
|
|
Broker Non-Vote
|
|
Chun
Kwok Alan Au
|
|
9,179,543
|
|
204,612
|
|
0
|
|
Gang
Ji
|
|
9,316,316
|
|
67,839
|
|
0
|
|
Bizuo
(Tony) Liu
|
|
9,301,819
|
|
82,336
|
|
0
|
(ii) To
ratify the appointment of BDO China Shu Lun Pan Certified Public
Accountants LLP as the Company’s independent registered
public accounting firm for the fiscal year ending December 31,
2017.
|
Shares Voted For
|
|
Shares Voted Against
|
|
Shares Abstaining
|
|
Broker Non-Vote
|
|
9,316,279
|
|
67,666
|
|
210
|
|
0
|
(iii)
To approve an amendment to the Cellular Biomedicine Group, Inc.
2014 Stock Incentive Plan to increase the number of shares
available for issuance thereunder by 1,000,000 shares.
|
Shares Voted For
|
|
Shares Voted Against
|
|
Shares Abstaining
|
|
Broker Non-Vote
|
|
8,399,504
|
|
982,861
|
|
1,790
|
|
0
|
(iv) To
conduct a non-binding advisory vote on the Company’s
executive compensation.
|
Shares Voted For
|
|
Shares Voted Against
|
|
Shares Abstaining
|
|
Broker Non-Vote
|
|
9,313,915
|
|
68,437
|
|
1,803
|
|
0
|
Item 7.01 Regulation FD
Disclosure.
On May
1, 2017, the Company issued a press release announcing the results
of the Annual Meeting. A copy of the press release is attached
hereto as Exhibit 99.1.
Item 9.01. Financial Statements and
Exhibits.
(d) Exhibits
99.1 Press
Release, dated May 1, 2017
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Cellular Biomedicine Group, Inc.
|
|
|
|
|
|
|
|
|
Date:
May 1, 2017
|
By:
|
/s/ Bizuo
(Tony) Liu
|
|
|
|
|
Bizuo
(Tony) Liu
|
|
|
|
|
Chief
Executive Officer
|
|
|
|
|
|
|